Erythrocyte membrane trenbolone acetate 100mg elasticity increases, reducing their adhesion, platelet aggregation and decreases blood viscosity. Blocks adenosine receptors.
During metabolism formed more active metabolites. The drug is derived primarily by the kidneys as metabolites. Less than 4% of the administered dose is excreted in the feces. In patients with liver function impaired bioavailability is increased and its half-life is prolonged.
Indications for use:
Peripheral circulatory disorders. Ischemic cerebral stroke; circulatory disorders of the brain by atherosclerosis, encephalopathy. Trophic disorders of tissues and organs associated with thrombosis of arteries or veins, varicose veins, frostbite. Diabetic angiopathy. Disorders of blood circulation in the vessels of the eyes, middle ear dysfunction of vascular origin, accompanied by hearing loss.
– Hypersensitivity to pentoxifylline and similar drugs and substances from the group of xanthine derivatives such as theophylline, caffeine, aminophylline or theobromine;
– acute myocardial infarction
– massive bleeding;
– bleeding in the brain;
– massive bleeding in the retina;
– age of 18 years ;
– pronounced coronary or cerebral arteriosclerosis;
– expressed cardiac arrhythmias;
– uncontrolled hypotension
Use in patients with labile blood pressure, tendency to arterial hypotension, heart failure, and liver and kidney, after recently transferred surgical intervention.
Pregnancy and lactation
Treatment of pregnant pentoxifylline contraindicated.
The drug passes into breast milk, so breastfeeding women should either refrain from feeding, or they should be assigned to other treatment.
Dosing and Administration
The drug may be administered intravenously, intraarterially.
Intravenously injected slowly at a dose of 0.1 g in 250-500 ml of isotonic sodium chloride solution or 5% glucose solution (duration of administration – 90180 min); intra – initially at a dose of 0.1 g in 20-50 ml of isotonic sodium chloride solution, and in the days that followed – by 0.2-0.3 g per 30-50 ml of solvent (introduction speed: 0.1 g (5 ml pentoxifylline 2% solution) for 10 minutes).
From the nervous trenbolone acetate 100mg system: headache, dizziness, anxiety, sleep disorders, convulsions;
For the skin: flushing of the face, “tides” of blood to the skin of the face and upper chest, swelling, increased fragility of nails;
From the gastrointestinal tract: kserotomiya, anorexia, intestinal, aggravation cholecystitis, cholestatic hepatitis.
From the senses: blurred vision, scotoma.
Cardio-vascular system: tachycardia, arrhythmia, false angina, the progression of angina, lower blood pressure;
On the part of the system and hemostasis of blood: thrombocytopenia, leukopenia, pancytopenia, gipofibrinogenemia, bleeding from vessels in the skin, mucous membranes of the stomach, intestines;
Allergic reactions: itching, hives, skin flushing, angioedema, anaphylactic shock;
Laboratory indicators: increase in activity of “liver” transaminases (ALT, ACT, LDH) and alkaline phosphatase.
The first signs of overdose: weakness, dizziness, tachycardia, and lowering blood pressure, the development of drowsiness, fainting, agitation, seizures.
Treatment is symptomatic: the maintenance or restoration of blood pressure, maintaining respiratory function.
Interaction with other drugs
– Pentoxifylline may increase the effects of other drugs that affect blood clotting (indirect and direct anticoagulants, thrombolytics)
– enhances the effect on the system clotting drugs such as cefamandole, ceftazidime, tsefotetan, valproic acid,
– pentoxifylline may exacerbate the effects of antihypertensive drugs, insulin, oral hypoglycemic agents;
– cimetidine increases the stable concentration of pentoxifylline in plasma, and therefore may be a more frequent occurrence of side effects of the latter;
Co-administration trenbolone acetate 100mg with other drugs in this group, it may enhance the CNS arousal.
Compatibility pentoxifylline solution, infusion solution should be checked in each case.
During the intravenous infusion the patient should be in a prone position.
The drug was well tolerated at the recommended infusion rate or by injection. For intravenous and intra-arterial administration of the drug should be careful. Dose should be reduced for patients with low blood pressure and unstable. Older people excretion of the drug decreases, and therefore may require a reduction in dose.
The safety and efficacy of pentoxifylline in children have not been studied.
Smoking may reduce the therapeutic efficacy of the drug.
Solution for intravenous or intraarterial administration of 20 mg / ml in 5 ml ampoules. 5 or 10 vials in a pack box. In each pack (box) put the knife scarifier ampoule or ampoule and instructions for use. When packaging the drug in capsules imported with a tension ring for an autopsy knife scarifier ampoule or do not invest.
10 ampoules in blisters. Blisters with instruction on use and knife ampoule is placed in a pack.